Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

RedHill Biopharma Announces New Opaganib Data For Nuclear Radiation Injury

By Vandana Singh
Yesterday, 1:08 PM
RedHill Biopharma Ltd (NASDAQ:RDHL) announced in vivo results from a new preclinical study evaluating the effects of opaganib] on radiation-induced hematologic…

RDHL

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Citing Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder

By Vandana Singh
Yesterday, 1:01 PM
Editas Medicine Inc (NASDAQ:EDIT) announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine. EDIT-101…

EDIT

Read More
1 minute read
  • FDA
  • News

Sanofi Says European Commission Approves Enjaymo For Treatment Of Hemolytic Anemia In Adult Patients With Cold Agglutinin Disease

By Benzinga Newsdesk
Yesterday, 12:52 PM
-Reuters

SNY

Read More
1 minute read
  • FDA
  • News

Oramed Announces Additional Safety, Efficacy Data From Phase 2 Clinical Trial Of ORMD-0801 For NASH; Achieved Primary Endpoint

By Benzinga Newsdesk
Yesterday, 12:28 PM
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat,

ORMP

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks

Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

By Vandana Singh
Yesterday, 11:03 AM
Evaxion Biotech A/S (NASDAQ:EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer…

EVAX

Read More
2 minute read
  • Cannabis
  • FDA
  • Markets
  • News
  • Penny Stocks

Incannex Initiates BA/BE Clinical Trial Evaluating IHL-42X In Obstructive Sleep Apnoea

By Nina Zdinjak
Yesterday, 10:59 AM
Cannabis and psychedelics-focused Pharma company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1 2023.

IXHL

Read More
1 minute read
  • Biotech
  • Cannabis
  • General
  • Markets
  • News
  • Penny Stocks

Israeli Canna-Tech Co. Teams Up With Another CPG Business, Here Are The Details

By Jelena Martinovic
Yesterday, 10:57 AM
BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) announced on Thursday that it has signed a deal for the provision of software services with an Israeli air conditioning company.

BCAN

Read More
1 minute read
  • FDA
  • News

On Nov 16, Inotiv Became Aware U.S. Attorney’s Office For Southern District Of Florida Criminally Charged Employees Of Supplier Of Non-Human Primates; Has Been Fully Cooperating, And Will Continue To Cooperate, With Department Of Justice

By Benzinga Newsdesk
Yesterday, 10:22 AM
- Reuters  

NOTV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Takeda Announces Phase 3 Trial Of ICLUSIG Met Primary Endpoint In Newly-Diagnosed Ph+ ALL, A Setting With No Targeted Treatments Approved In The US

By Benzinga Newsdesk
Yesterday, 8:01 AM
- The PhALLCON Study Is the First Global, Phase 3, Registrational, and Only Head-To-Head Clinical Trial Comparing Two TKIs in Frontline Ph+ ALL - Primary Endpoint Result Shows Superiority Compared to Imatinib as

TAK

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection

By Vandana Singh
Yesterday, 7:41 AM
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have initiated a Phase 1 study to evaluate the safety, tolerability, and immunogenicity of…

BNTX

Posts pagination

Previous 1 … 625 626 627 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service